Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Differential treatment options for left- and right-sided mCRC

Chiara Cremolini • 4 Jun 2022
ASCO 2022
Colorectal Cancer Gastrointestinal Cancer Antibodies Bevacizumab Panitumumab

Chiara Cremolini, MD, PhD, University of Pisa, Pisa, Italy, provides an overview of therapeutic strategies for patients with RAS wildtype metastatic colorectal cancer (mCRC). Whilst there are novel options for patients with left-sided mCRC including combination therapies consisting of anti-EFGR therapies such as panitumumab with mFOLFOX6, more research is needed to provide efficacious options for patients with right-sided mCRC. Immunotherapy is additionally a viable treatment strategy for patients with microsatellite-instable mCRC. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Chiara Cremolini

2:55
State-of-the-art first-line therapy for mCRC
Chiara Cremolini • 9 Sep 2022
1:22
Influence of sidedness on prognosis and treatment in mCRC
Chiara Cremolini • 9 Sep 2022
2:22
Interpreting real-world data to better manage patients with mCRC
Chiara Cremolini • 9 Sep 2022
2:43
PARADIGM: Panitumumab plus mFOLFOX6 in RAS wt mCRC
Chiara Cremolini • 4 Jun 2022

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals